Aquatic Capital Management LLC Purchases 60,688 Shares of Cencora, Inc. (NYSE:COR)

Aquatic Capital Management LLC boosted its stake in shares of Cencora, Inc. (NYSE:COR - Free Report) by 185.6% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 93,388 shares of the company's stock after purchasing an additional 60,688 shares during the quarter. Aquatic Capital Management LLC's holdings in Cencora were worth $20,982,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in the stock. Hickory Asset Management Inc. bought a new stake in shares of Cencora in the fourth quarter valued at approximately $572,000. Sylvest Advisors LLC bought a new stake in shares of Cencora in the fourth quarter valued at approximately $1,105,000. Insight Wealth Strategies LLC boosted its position in shares of Cencora by 124.6% in the fourth quarter. Insight Wealth Strategies LLC now owns 20,249 shares of the company's stock valued at $4,549,000 after acquiring an additional 11,232 shares during the period. Vontobel Holding Ltd. boosted its position in shares of Cencora by 46.9% in the fourth quarter. Vontobel Holding Ltd. now owns 6,245 shares of the company's stock valued at $1,403,000 after acquiring an additional 1,995 shares during the period. Finally, Thurston Springer Miller Herd & Titak Inc. boosted its position in shares of Cencora by 71.1% in the fourth quarter. Thurston Springer Miller Herd & Titak Inc. now owns 7,048 shares of the company's stock valued at $1,583,000 after acquiring an additional 2,928 shares during the period. Institutional investors own 97.52% of the company's stock.

Insider Transactions at Cencora

In related news, EVP Silvana Battaglia sold 5,000 shares of the business's stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $242.24, for a total transaction of $1,211,200.00. Following the completion of the sale, the executive vice president now directly owns 15,374 shares of the company's stock, valued at $3,724,197.76. The trade was a 24.54 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Chairman Steven H. Collis sold 14,578 shares of the business's stock in a transaction that occurred on Tuesday, March 25th. The stock was sold at an average price of $269.51, for a total transaction of $3,928,916.78. Following the sale, the chairman now directly owns 317,913 shares of the company's stock, valued at approximately $85,680,732.63. This trade represents a 4.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 50,223 shares of company stock worth $13,580,967. Corporate insiders own 10.80% of the company's stock.

Cencora Price Performance

NYSE:COR traded up $2.37 on Tuesday, reaching $290.12. The stock had a trading volume of 1,250,227 shares, compared to its average volume of 1,523,456. The company has a market capitalization of $56.26 billion, a P/E ratio of 41.27, a price-to-earnings-growth ratio of 1.31 and a beta of 0.55. Cencora, Inc. has a 1-year low of $214.77 and a 1-year high of $296.65. The company has a quick ratio of 0.54, a current ratio of 0.92 and a debt-to-equity ratio of 16.40. The stock has a fifty day moving average price of $268.94 and a 200-day moving average price of $250.00.

Cencora (NYSE:COR - Get Free Report) last released its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 EPS for the quarter, beating analysts' consensus estimates of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. Research analysts forecast that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, March 3rd. Stockholders of record on Friday, February 14th were given a dividend of $0.55 per share. The ex-dividend date was Friday, February 14th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.76%. Cencora's payout ratio is 31.29%.

Analysts Set New Price Targets

Several research firms have recently weighed in on COR. Evercore ISI increased their price objective on Cencora from $270.00 to $280.00 and gave the company an "outperform" rating in a research report on Thursday, February 6th. Morgan Stanley set a $288.00 target price on Cencora in a research note on Tuesday, April 15th. StockNews.com upgraded Cencora from a "hold" rating to a "buy" rating in a research note on Wednesday, March 12th. JPMorgan Chase & Co. upped their target price on Cencora from $289.00 to $301.00 and gave the company an "overweight" rating in a research note on Friday, January 24th. Finally, Bank of America upped their target price on Cencora from $270.00 to $285.00 and gave the company a "neutral" rating in a research note on Friday, April 11th. Two analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $289.09.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.